Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

Highlights • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options aft...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 38; no. 12; pp. 1381 - 1391
Main Authors Santini, Valeria, Prebet, Thomas, Fenaux, Pierre, Gattermann, Norbert, Nilsson, Lars, Pfeilstöcker, Michael, Vyas, Paresh, List, Alan F
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2014
Subjects
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine
Azacitidine - therapeutic use
Biomarkers
Cancer and Oncology
Cancer och onkologi
Clinical Medicine
Consensus
Disease-Free Survival
Europe - epidemiology
Hematology, Oncology and Palliative Medicine
Humans
Hypomethylating agents
Klinisk medicin
MDS
Medical and Health Sciences
Medicin och hälsovetenskap
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Practice Guidelines as Topic
Refractory
Relapse
Risk Factors
Salvage therapy
Survival Rate
Europe
Refractory
Relapse
Azacitidine
Hypomethylating agents
MDS
Consensus
Salvage therapy
Online AccessGet full text

Cover

More Information
Summary:Highlights • Not all patients with higher-risk MDS treated with azacitidine respond to treatment. • Furthermore, the vast majority of responders to treatment subsequently relapse. • No standard of care has been established for patients after failure of azacitidine. • We discuss treatment options after loss of response or progression on azacitidine. • In addition, we consider optimization of first-line treatment with azacitidine.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0145-2126
1873-5835
1873-5835
DOI:10.1016/j.leukres.2014.09.008